Your browser doesn't support javascript.
loading
Emerging Structure-Function Paradigm of Endocrine FGFs in Metabolic Diseases.
Luo, Yongde; Ye, Sheng; Li, Xiaokun; Lu, Weiqin.
Afiliação
  • Luo Y; School of Pharmaceutical Science, Wenzhou Medical University, Center for Cancer and Metabolism Research, Institute for Life Science, Wenzhou University, Wenzhou, Zhejiang 325000, China; Proteomics and Nanotechnology Laboratory, Center for Cancer and Stem Cell Biology, Institute of Biosciences and Te
  • Ye S; School of Life Science, Tianjin University, Tianjin 300072, China; Life Sciences Institute and Innovation Center for Cell Signaling Network, Zhejiang University, Huangzhou, Zhejiang 310058, China. Electronic address: sye@tju.edu.cn.
  • Li X; School of Pharmaceutical Science, Wenzhou Medical University, Center for Cancer and Metabolism Research, Institute for Life Science, Wenzhou University, Wenzhou, Zhejiang 325000, China. Electronic address: lixk1964@163.com.
  • Lu W; Division of Gastroenterology and Hepatology, Department of Medicine, Stony Brook University School of Medicine, 101 Nicolls Road, Stony Brook, NY 11794, USA. Electronic address: Weiqin.Lu@stonybrookmedicine.edu.
Trends Pharmacol Sci ; 40(2): 142-153, 2019 02.
Article em En | MEDLINE | ID: mdl-30616873
Endocrine fibroblast growth factors (eFGFs) control pathways that are crucial for maintaining metabolic homeostasis of lipids, glucose, energy, bile acids, and minerals. Unlike the heparin-binding paracrine FGFs, eFGFs require a unique Klotho family protein to form a productive triad complex, but the structural and mechanistical details of this complex have remained obscure since the beginning of the eFGF field. However, recent breakthroughs in resolving the 3D structures of eFGF signaling complexes have now unveiled the atomic details of multivalent interactions among eFGF, FGFR, and Klotho. We provide here a timely review on the architecture and the structure-function relationships of these complexes, and highlight how the structural knowledge opens a new door to structure-based drug design against a repertoire of eFGF-associated metabolic diseases.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fatores de Crescimento de Fibroblastos / Doenças Metabólicas Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: Trends Pharmacol Sci Ano de publicação: 2019 Tipo de documento: Article País de publicação: Reino Unido

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fatores de Crescimento de Fibroblastos / Doenças Metabólicas Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: Trends Pharmacol Sci Ano de publicação: 2019 Tipo de documento: Article País de publicação: Reino Unido